Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study
Frontiers in Gastroenterology · 27.07.2026 · 5
DOI: 10.3389/fgstr.2026.1874051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Gastroenterology, online erschienen am 27.07.2026. Verfasst von Bolette Christophersen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ferring Pharmaceuticals A/S, Copenhagen, Denmark. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferring Pharmaceuticals.
Abstract (Originalsprache)
Introduction
Optimised oral mesalazine therapy (4 or 4.8 g/day depending on the formulation) has been associated with better outcomes than lower doses in mild-to-moderate ulcerative colitis (UC). The aim of this post-hoc analysis of the IMPACT study was to provide a greater understanding of the influence of disease severity on the outcomes in patients with mild-to-moderate UC receiving oral mesalazine.
Methods
IMPACT was a Dutch, phase 4, non-interventional, observational, 12-month prospective study that enrolled 151 adult patients with mild-to-moderate UC who received oral prolonged-release mesalazine de novo or had a dose escalation for an active episode (NCT02261636). The current analysis compared the outcomes in patients receiving mesalazine 4 g/day versus 2–3 g/day.
Results
Of 147 patients (median age = 46 years, 47.6% women), 139 (94.6%) received 4 g/day, mostly as prolonged-release mesalazine granules (74.2%). Recurrence was significantly reduced for patients on 4 g/day versus 2–3 g/day (26.6% vs. 62.5%, p = 0.03). There was a trend towards a longer disease-free interval for those on the optimised dose over the 12-month period (mean = 16.8 vs. 12.8 months, p = 0.49). Time to recurrence was similar ( p = 0.241) for patients with milder [Ulcerative Colitis Disease Activity Index (UCDAI) scores ≤3] versus more moderately active disease (scores ≥4), with a significantly higher rate of combined oral plus topical therapy in the latter (23.2% vs. 46.1%, p = 0.004). Patients’ preferred formulation was granules (68.0%) given once daily (78.7%), with good adherence to all formulations (≥8.5/10, high = 10) irrespective of regimen ( p = 0.873).
Discussion
Optimised mesalazine treatment improved the clinical outcomes in patients across the spectrum of mild-to-moderate UC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
- Violicom Medical Limited, Aldermaston, United Kingdom.
- Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
Förderung
- Ferring Pharmaceuticals
Zitieren
APA
Christophersen, B., Fullarton, J., & West, R. (2026). Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study. Frontiers in Gastroenterology, 5. https://doi.org/10.3389/fgstr.2026.1874051
Vancouver
Christophersen B, Fullarton J, West R. Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study. Frontiers in Gastroenterology. 2026;5. doi:10.3389/fgstr.2026.1874051
BibTeX
@article{Christophersen2026,
author = {Christophersen, Bolette and Fullarton, John and West, Rachel},
title = {Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study},
journal = {Frontiers in Gastroenterology},
year = {2026},
volume = {5},
doi = {10.3389/fgstr.2026.1874051}
}
EUVIMED